CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 8 of the 11 sources its claims cite were checked for support.

Weight regain after cessation of medication for weight management: systematic review and meta-analysis

Open access

Abstract

Objectives: To quantify and compare the rate of weight regain after cessation of weight management medications (WMMs) in adults with overweight or obesity. Design: Systematic review and meta-analysis. Study selection: Trial registries and databases (Medline, Embase, PsycINFO, CINAHL, Cochrane, Web of Science, and trial registries) were searched from inception until February 2025 for randomised controlled trials (RCTs), non-randomised trials, and observational studies that included WMM (≥8 weeks) with follow-up for ≥4 weeks after cessation of treatment in adults with overweight or obesity. Comparators were any non-drug weight loss intervention or placebo. Data extraction and synthesis: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Two independent reviewers screened titles, extracted data, and assessed the risk of bias using the Cochrane Risk of Bias 2 tool for RCTs and the ROBINS-I tool for non-randomised trials. Data were analysed using mixed effect, meta-regression, and time-to-event models. Weight regain after cessation of WMM was compared with that reported after cessation of behavioural weight management programmes (BWMPs). Main outcome measures: The primary outcome was rate of weight regain from end of treatment, with associated changes in cardiometabolic markers as a secondary outcome. Results: Of the 9288 titles screened, 37 studies (63 intervention arms, 9341 participants) were included. Average treatment duration was 39 (range 11-176) weeks, with average follow-up of 32 (4-104) weeks. The average monthly rate of weight regain was 0.4 kg (95% confidence interval (CI) 0.3 to 0.5) (mixed model 0.3 kg (0.2 to 0.4) monthly v control in RCTs). All cardiometabolic markers were projected to return to baseline within 1.4 years after the cessation of WMM. Weight regain was faster after WMM than after BWMP (by 0.3 kg (0.22 to 0.34) monthly), independent of initial weight loss. Estimates and precision were robust in sensitivity analyses. Conclusions: This review found that cessation of WMM is followed by rapid weight regain and reversal of beneficial effects on cardiometabolic markers. Regain after WMM was faster than after BWMP. These findings suggest caution in short term use of these drugs without a more comprehensive approach to weight management. Systematic review registration: PROSPERO CRD42024532069.

Overview

CoChat Summary

## TL;DR

This systematic review and meta-analysis found that adults stop weight management medications and then regain weight quickly, at an average rate of 0.4 kg per month, with projected return to baseline weight by 1.7 years. Cardiometabolic benefits also faded after stopping treatment, and weight regain was faster than after stopping behavioural weight management programmes.

## Key findings

  • The review included 37 studies (63 intervention arms) and 9,341 participants; the average treatment duration was 39 weeks and average follow-up after stopping was 32 weeks.
  • Across all weight management medications (WMMs), the average monthly rate of weight regain was 0.4 kg (95% CI 0.3 to 0.5); in randomised controlled trials, the mixed model estimated 0.3 kg (0.2 to 0.4) monthly versus control.
  • Weight regain was faster for newer and more effective incretin mimetics: 0.8 kg/month (95% CI 0.7 to 0.9), with projected return to baseline weight by 1.5 years.
  • Cardiometabolic markers also worsened after cessation: HbA1c, fasting glucose, systolic/diastolic blood pressure, total cholesterol, and triglycerides were projected to return to baseline within 1 to 1.4 years after stopping WMMs.

## Methods

  • Systematic review and meta-analysis, prospectively registered in PROSPERO (CRD42024532069) and conducted according to PRISMA/Cochrane methods.
  • Searched Medline, Embase, PsycINFO, CINAHL, Cochrane, Web of Science, and trial registries from inception to February 2025 for RCTs, non-randomised trials, and observational studies of adults with overweight or obesity using WMMs for at least 8 weeks and with at least 4 weeks of follow-up after cessation.
  • Primary analyses used mixed models, meta-regression, and time-to-event models; secondary analyses examined cardiometabolic markers and compared WMMs with previously published behavioural weight management programme data.

## Limitations

  • The paper states that data for the newer and more effective incretin mimetics were limited to only 8 studies with a maximum of 12 months’ follow-up after cessation, so estimates beyond that point were projected.
  • The paper states that the comparison with behavioural weight management programmes was indirect, and populations may have differed slightly between reviews.
  • The paper states that few studies were at low risk of bias; it also notes that weight regain was modeled as linear, although a sensitivity analysis found no evidence of departure from linearity.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmj-2025-085304

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC BY · PubMed Central
Fig 1 Change in body weight (kg) from baseline (treatment start) for all studies using all weight management medications (top panel), all incretin mimetics (middle panel), and newer and more effective incretin mimetics (semaglutide and tirzepatide) (bottom panel). Solid orange line shows the amount of weight loss during treatment (in the blue shaded area) followed by the rate of weight regain after treatment end (95% confidence interval) as estimated by mixed effects model (model 1); dashed orange line is an extension of the model prediction line to depict the length of time for body weight to return to baseline, as follow-up data were not available beyond 52 weeks for newer and more effective incretin mimetics; and blue lines display individual studies included in the analysis
Fig 1 Change in body weight (kg) from baseline (treatment start) for all studies using all weight management medications (top panel), all incretin mimetics (middle panel), and newer and more effective incretin mimetics (semaglutide and tirzepatide) (bottom panel). Solid orange line shows the amount of weight loss during treatment (in the blue shaded area) followed by the rate of weight regain after treatment end (95% confidence interval) as estimated by mixed effects model (model 1); dashed orange line is an extension of the model prediction line to depict the length of time for body weight to return to baseline, as follow-up data were not available beyond 52 weeks for newer and more effective incretin mimetics; and blue lines display individual studies included in the analysisCC BY · PubMed Central
Fig 2 Difference in change in body weight (kg) from baseline (treatment start) between intervention and control for randomised controlled trials using all weight management medications (top panel), all incretin mimetics (middle panel), and newer and more effective incretin mimetics (semaglutide and tirzepatide) (bottom panel). Solid orange line shows the amount of weight loss during treatment (in the blue shaded area) followed by the rate of weight regain after treatment end (95% confidence interval) compared with control, estimated by mixed effects model (model 1); and blue lines display change in body weight in intervention group relative to control for studies included in the analysis
Fig 2 Difference in change in body weight (kg) from baseline (treatment start) between intervention and control for randomised controlled trials using all weight management medications (top panel), all incretin mimetics (middle panel), and newer and more effective incretin mimetics (semaglutide and tirzepatide) (bottom panel). Solid orange line shows the amount of weight loss during treatment (in the blue shaded area) followed by the rate of weight regain after treatment end (95% confidence interval) compared with control, estimated by mixed effects model (model 1); and blue lines display change in body weight in intervention group relative to control for studies included in the analysisCC BY · PubMed Central
Fig 3 Change in cardiometabolic markers from baseline (treatment start) for all studies included in the review. Solid orange line shows change during treatment (in the blue shaded area) and rate of change after treatment end (95% confidence intervals) as estimated by mixed effects model (model 1); and blue lines display individual studies included in the analysis
Fig 3 Change in cardiometabolic markers from baseline (treatment start) for all studies included in the review. Solid orange line shows change during treatment (in the blue shaded area) and rate of change after treatment end (95% confidence intervals) as estimated by mixed effects model (model 1); and blue lines display individual studies included in the analysisCC BY · PubMed Central
Fig 4 Change in body weight (kg) from baseline (treatment start) (left panel) and for a fixed amount (5 kg, 10 kg, and 15 kg) of weight loss (right panel) after treatment with WMM or BWMPs. Solid lines show weight loss during treatment (in the blue shaded area) and rate of weight regain after treatment end (95% confidence interval) estimated using mixed effects model (model 1). BWMP=behavioural weight management programme; WMM=weight management medication
Fig 4 Change in body weight (kg) from baseline (treatment start) (left panel) and for a fixed amount (5 kg, 10 kg, and 15 kg) of weight loss (right panel) after treatment with WMM or BWMPs. Solid lines show weight loss during treatment (in the blue shaded area) and rate of weight regain after treatment end (95% confidence interval) estimated using mixed effects model (model 1). BWMP=behavioural weight management programme; WMM=weight management medicationCC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 0 Not valid · 2 Not checked · 64 Own results and interpretations

29 more claims · 1 with their cited sources checked

Create a free account to see all 74 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 35
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. Samp, 2015, Effect of Orlistat and Sibutramine Cessation on Obesity Indices and Cardiovascular Risk Factors in Obese Subjects, Int Med J, 22, 232

Cited by

See all 174

Metadata

Authors
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., Jebb, S. A., & Koutoukidis, D. A.
Affiliations
  • National Institute for Health and Care Research (GB)
  • Warneford Hospital (GB)
  • University of Oxford (GB)
Corresponding author
West, Sam
Venue
BMJ
Publisher
BMJ
Published
2026-01-07
Volume
392
Pages
e085304
ISSN
1756-1833 (ISSN-L)
OpenAlex
W7118883589
Cited by
174
References
55
Citations by year
2026: 173
FWCI
178.56
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
Wellcome Trust (225494/Z/22/Z)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
weight regain, obesity, overweight, cardiometabolic biomarkers, weight loss maintenance
MeSH terms
Adult, Humans, Obesity, Weight Gain, Weight Loss, Anti-Obesity Agents, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Weight regain after cessation of medication for weight management: systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/bmj-2025-085304
The paper
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., Jebb, S. A., & Koutoukidis, D. A. (2026). Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. https://doi.org/10.1136/bmj-2025-085304

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.